>
Switch to:

Illumina Ending Cash Position

: $1,351 Mil (As of Mar. 2022)
View and export this data going back to 2000. Start your Free Trial

Illumina's Ending Cash Position for the quarter that ended in Mar. 2022 was $1,351 Mil.

Illumina's quarterly Ending Cash Position increased from Sep. 2021 ($1,080 Mil) to Dec. 2021 ($1,232 Mil) and increased from Dec. 2021 ($1,232 Mil) to Mar. 2022 ($1,351 Mil).

Illumina's annual Ending Cash Position declined from Dec. 2019 ($2,042 Mil) to Dec. 2020 ($1,810 Mil) and declined from Dec. 2020 ($1,810 Mil) to Dec. 2021 ($1,232 Mil).

Illumina Ending Cash Position Historical Data

The historical data trend for Illumina's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Ending Cash Position
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,225.00 1,144.00 2,042.00 1,810.00 1,232.00

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Ending Cash Position Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,433.00 4,196.00 1,080.00 1,232.00 1,351.00

Illumina Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Illumina's Ending Cash Position for the fiscal year that ended in Dec. 2021 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1810+-578
=1,232

Illumina's Ending Cash Position for the quarter that ended in Mar. 2022 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1232+119
=1,351

Illumina Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Illumina's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina Business Description

Illumina logo
Industry
Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071
Comparable Companies
NAS:IDXX NYSE:MTD NYSE:A NYSE:LH NYSE:IQV NYSE:WAT NYSE:PKI NAS:ICLR NYSE:DGX NYSE:CRL NYSE:TMO NYSE:DHR SHSE:603259 XSWX:LONN XPAR:ERF SZSE:300347 XPAR:BIM ASX:SHL NYSE:QGEN NAS:EXAS
Traded in Other Exchanges
ILMN:Mexico 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany I1LM34:Brazil ILMN:Austria
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Website
https://www.illumina.com
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

From GuruFocus

Vontobel Holding Ltd. Buys Illumina Inc, Sells Intuitive Surgical Inc, Arista Networks Inc, InMode

By insider 02-11-2022

GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test

By Business Wire 12-06-2021

Illumina To Webcast Upcoming Investor Conference

By PRNewswire 12-23-2021

Illumina delivers 2021 results ahead of expectations, strong 2022 guidance and deep pipeline of long-term growth opportunities at 2022 J.P. Morgan Healthcare Conference

By PRNewswire 01-10-2022

Telos Capital Management, Inc. Buys Illumina Inc, United Parcel Service Inc, Newell Brands Inc, Sells Activision Blizzard Inc, iShares Biotechnology ETF, Merck Inc

By insider 01-21-2022

Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia

By PRNewswire 01-24-2022

GRAIL and Point32Health Collaborate to Offer Galleri® Multi-Cancer Early Detection Blood Test

By PRNewswire 02-15-2022

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

By PRNewswire 01-10-2022

Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices

By GuruFocusNews 01-04-2022

Slow Capital, Inc. Buys Wolfspeed Inc, Bloom Energy Corp, Illumina Inc, Sells Apollo Global Management Inc, iShares iBoxx USD High Yield Corporate Bond ETF, SPDR Bloomberg High Yield Bond ETF

By insider 02-09-2022

Other Sources

Company News for Jan 12, 2022

By Zacks 2022-01-12

Illumina (ILMN) to Address Nasopharynx Cancer With New Pact

By Zacks 2022-02-07

Illumina (ILMN) Invests in Seven Additional Genomics Startups

By Zacks 2022-03-18

Illumina (ILMN) Debuts TSO Comprehensive Test in Europe

By Zacks 2022-03-18

Why Illumina Stock Just Jumped 9.5%

By Fool 2022-01-11

4 Toxic Stocks to Eliminate From Your Portfolio Now

By Zacks 2021-12-27

Top Research Reports for Merck, Shopify & Intercontinental Exchange

By Zacks 2022-02-18

Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse

By tipranks.com 2022-03-02

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

By Zacks 2022-01-13

Here's Why You Should Hold on to Illumina (ILMN) for Now

By Zacks 2022-01-14

$ILMN - Illumina's (ILMN) CEO Francis deSouza on Q4 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2022-02-10

These 2 Nasdaq Winners Are Lighting Up the Market Tuesday

By Fool 2022-01-11

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

By Zacks 2022-02-03

Are Illumina and Beam Therapeutics the Healthcare Industry's Rising Stars?

By Fool 2022-01-22

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

By Zacks 2021-12-15

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)